教師簡介

  • 特聘教授
  • 蔡亭芬
  • Ting-Fen Tsai
  • (O) 02-28267293; (Lab) 02-28267000 ext. 5662
  • tftsai@ym.edu.tw
  • 傳統醫學大樓乙棟7樓R707
  • 專業領域
  • 長壽基因與老化生物學、抗老化藥物開發、肝癌形成分子機轉、小鼠遺傳學與人類疾病模式
  • 研究方向
  • The long-term objective of Dr. Tsai’s research interest is to apply mouse genetics approach to elucidate basic molecular and biochemical pathways that regulate mammalian development and homeostasis, and to apply this to the development of new prevention and therapeutic agents for human disorders resulting from the dysregulation of these pathways. A common theme is to take an approach involving the flow of information from the study of human cancers and genetic diseases, to the generation and modeling of human diseases in genetically modified mice, to the testing of hypotheses and evaluation of the phenotypic consequences of gain-of-function of transgenes and/or loss-of-function of endogenous genes, and finally, to the development of treatment protocols using these mouse models.

    Dr. Tsai’s lab has contributed to the characterization of a longevity candidate gene, Cisd2, which is located within the longevity region on human chromosome 4q. Using a mouse genetics approach, the lab had demonstrated for the first time that Cisd2 is involved in mammalian lifespan control. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Dr. Tsai’s lab effectively links Cisd2 gene function, mitochondrial integrity and aging in mammals. Furthermore, Dr. Tsai’s group demonstrated that a persistent level of Cisd2 extends healthy lifespan and delays aging in mice. Current studies are focused on (1) exploring the possibility of drug-stimulated Cisd2 expression in mammals; (2) investigating the molecular mechanism underlying the control of lifespan by Cisd2 in mammals; (3) dissect the primary and secondary effects of Cisd2 on phenotypes using tissue-specific knockout mice; and (4) examining the Cisd2 expression levels in various human populations during the aging process, and specifically to compare gene activity and/or protein function between normal populations and long-lived centenarian groups.

    Dr. Tsai’s lab is also focused on the study of cancers and cell cycle dysregulation under in vivo physiological condition with particular emphasis on the hepatocellular carcinoma, liver regeneration and liver pathogenesis in mice. Examples of current projects are (1) unraveling the effects of HBV gene products, e.g. X protein, mutant surface antigens, on liver pathogenesis and cancer development; (2) investigating the haplo-insufficient effects of Cisd2 on HCC development in Cisd2 transgenic and knockout mice; (3) developing a platform by using mouse models established in the lab for evaluating and/or screening of chemoprevention and therapeutic agents.

  • 教授科目
  • 發育生物學
    遺傳學
    分子生物學
    生化及細胞分子生物學
    生命科學技術
  • 經歷
  • 2017-present
    國立陽明大學
    生命科學系暨基因體科學研究所
    特聘教授
  • 2012-present
    國家衛生研究院
    分子與基因醫學研究組
    合聘研究員
  • 2010-2017
    國立陽明大學
    生命科學系暨基因體科學研究所
    教授
  • 2012-2015
    國立陽明大學
    生命科學系暨基因體科學研究所
    所長及系主任
  • 2010-2012
    國立陽明大學
    實驗動物照護及使用委員會(IACUC)
    主委
  • 2001-2012
    臺北榮總教研部
    特約副研究員、特約研究員
  • 2004-2011
    國家衛生研究院
    分子與基因醫學研究組
    合聘助研究員、兼任副研究員
  • 2006-2009
    國立陽明大學
    生命科學系暨基因體科學研究所
    副教授
  • 1999-2005
    國立陽明大學
    生命科學系、遺傳學研究所
    助理教授
  • 1995-1999
    Associate of Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas, USA
  • 1995-1999
    美國德州貝勒醫學院
    分子暨人類遺傳學系
    博士後研究員
  • 1987-1989
    臺北榮總教研部
    研究助理
  • 學歷
  • 1995
    國立陽明大學
    微生物暨免疫學研究所
    博士
  • 1987
    國立陽明醫學院
    微生物暨免疫學研究所
    碩士
  • 1985
    東海大學生物系
    學士

代表著作

    期刊論文(2013-present)

  • Shen ZQ, Huang YL, Tsai TF*. CISD2 haploinsufficiency: a driving force for hepatocellular carcinoma. Molecular & Cellular Oncology, Published online: 13 Mar 2018.
  • Hung JH, Li CH, Yeh CH, Huang PC, Fang CC, Chen YF, Lee KJ, Chou CH, Cheng HY, Huang HD, Chen M, Lin A, Tsai TF, Yen CH, Tsou AP, Tyan YC, Chen YA. MicroRNA-224 down-regulates Glycine N-methyltransferase gene expression in Hepatocellular Carcinoma. Scientific Reports 8(1): 12284 (2018).
  • Wu SY, Lan SH, Wu SR, Chiu YC, Lin XZ, Su IJ, Tsai TF, Yen CJ, Lu TH, Liang FW, Li CY, Su HJ, Su CL, Liu HS. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology 68: 141-154 (2018).
  • Huang YL, Shen ZQ, Wu CY, Teng YC, Liao CC, Kao CH, Chen LK, Lin CH*, Tsai TF*. Comparative proteomic profiling reveals a role of Cisd2 in skeletal muscle aging. Aging Cell 17: e12705 (2018).
  • Shen ZQ, Chen YF, Chen JR, Jou YS, Wu PC, Kao CH, Wang CH, Huang YL, Huang TS, Shyu YC, Tsai SF, Kao LS, Tsai TF*. CISD2 haploinsufficiency disrupts calcium homeostasis, causes nonalcoholic fatty liver disease and promotes hepatocellular carcinoma. Cell Reports 21: 2198-2211 (2017).
  • Teng YC, Neo JC, Wu JC, Chen YF, Kao CH, Tsai TF*. Expression of a hepatitis B virus Pre-S2 deletion mutant in liver results in hepatomegaly and hepatocellular carcinoma in mice. The Journal of Pathology 241: 463-474 (2017).
  • Cheng YH, Lin FH, Wang CY, Hsiao CY, Chen HC, Kuo HY, Tsai TF, Chiou SH. Recovery of oxidative stress-induced damage in Cisd2-deficient cardiomyocytes by sustained release of ferulic acid from injectable hydrogel. Biomaterials 103: 207-218 (2016).
  • Teng YC, Shen ZQ, Kao CH, Tsai TF*. HCC mouse models: HBV-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World Journal of Gastroenterology 22(1): 300-325 (2016).
  • Liu CC, Lin YC, Chen YH, Chen CM, Pang LY, Chen HA, Wu PR, Lin MY, Jiang ST, Tsai TF, Chen RH. Cul3-KLHL20 ubiquitin ligase governs the turnover of ULK1 and VPS34 complexes to control autophagy termination. Molecular Cell 61(1): 84-97 (2016).
  • Wang CH, Tsai TF, Wei YH. Role of mitochondrial dysfunction and dysregulation of Ca2+ homeostasis in insulin insensitivity of mammalian cells. Ann N Y Acad Sci. 1350(1): 66-76. (2015).
  • Tsai PH, Chien Y, Chuang JH, Chou SJ, Chien CH, Lai YH, Li HY, Ko YL, Chang YL, Wang CY, Liu YY, Lee HC, Yang CH, Tsai TF, Lee YY, Chiou SH. Dysregulation of Mitochondrial Functions and Osteogenic Differentiation in Cisd2-deficient Murine Induced Pluripotent Stem Cells. Stem Cells Dev. 24(21): 2561-2576 (2015).
  • Wang SH, Yeh SH, Shiau CW, Chen KF, Lin WH, Tsai TF, Teng YC, Chen DS and Chen PJ. Sorafenib inhibits hepatitis B virus X activated oncogenic androgen pathway in liver through SHP-1. J Natl Cancer Inst. 23;107(10) (2015).
  • Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, Liu KJ, Chang GC, Tsai TF, Tsai SF, Liu HP, Wu YC, Chen YT, Huang SF, Chen YR. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. BBA-Molecular Basis of Disease 1852(7):1540-1549 (2015).
  • Teng CF, Hsieh WC, Yang CW, Su HM, Tsai TF, Sung WC, Huang W, Su IJ. A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis. Molecular Carcinogenesis 2015 Jan 15. doi: 10.1002/mc.22266. [Epub ahead of print].
  • Shiue SC, Huang MZ, Tsai TF, Chang A, Choo K, Huang CJ, Su TS. Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model. J Biomed Sci. 22(1):10 (2015).
  • Wu KC, Lu YH, Peng YH, Tsai TF, Kao YH, Yang HT, Lin CJ. Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice. J Cereb Blood Flow Metab.35(1):37-47 (2015).
  • Wang CH, Kao CH, Chen YF, Wei YH, Tsai TF*. Cisd2 mediates lifespan: Is there an interconnection among Ca2+ homeostasis, autophagy and lifespan? Free Radical Research 48(9): 1109-1114 (2014).
  • Wang CH, Chen YF, Wu CY, Wu PC, Huang YL, Kao CH, Lin CH, Kao LS, Tsai TF*, Wei YH*. Cisd2 modulates differentiation and functioning of adipocytes by regulating intracellular Ca2+ homeostasis. Human Molecular Genetics 23(18): 4770-4785 (2014).
  • Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis. Autophagy 10(9): 1687-1689 (2014).
  • Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of miR-224. Hepatology 59(2): 505-517 (2014).
  • Wiley SE, Andreyev AY, Karisch R, Perkins G, Wall EA, van der Geer P, Chen YF, Tsai TF, Simon MI, Neel BG, Dixon JE, Murphy AN. Wolfram Syndrome protein, Miner1 (Cisd2), regulates sulfhydryl redox status, the unfolded protein response and Ca2+ homeostasis. EMBO Molecular Medicine 5(6): 904-918 (2013).
  • Hsieh WC, Yang CW, Haung YS, Chao TW, Tsai TF, Su IJ. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarinin transgenic mice. Functional Foods in Health and Disease 3(9): 341-352 (2013).
  • Yang CY, Chen JB, Tsai TF, Tsai YC, Tsai CY, Liang PH, Hsu TL, Wu CY, Netea MG, Wong CH, Hsieh SL. CLEC4F is an inducible C-type lectin in F4/80-positive cells and is involved in alpha-galactosylceramide presentation in liver. PLoS ONE 8(6): e65070 (2013).
  • Hsieh YH, Su IJ, Yen CJ, Tsai TF, Tsai HW, Tsai HN, Huang YJ, Chen YY, Ai YL, Kao LY, Hsieh WC, Wu HC, Huang W. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients. Carcinogenesis 34(2): 475-485 (2013).
  • 期刊論文(1988-2012)

  • Wu CY, Chen YF, Wang CH, Kao CH, Zhuang HW, Chen CC, Chen LK, Kirby R, Wei YH, Tsai SF, Tsai TF*. A persistent level of Cisd2 extends healthy lifespan and delays aging in mice. Human Molecular Genetics 21(18): 3956-3968 (Cover Story; Sept 15, 2012).
  • Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. Journal of Clinical Investigation 122(8): 2884-2897 (2012).
  • Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, Tsai TF*. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prevention Research 5(7): 952-962 (2012).
  • Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKK to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS ONE 7(7): e41931 (2012).
  • Klionsky DJ and 1269 others (incl. Tsai TF). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4): 445-544 (2012).
  • Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, Tsai TF, Chang KW, Shieh GS, Tsai SF, Wang HD, Yuh CH. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 33(1): 209-219 (2012).
  • Wang EY, Yeh SH, Tsai TF, Huang PH, Jeng YM, Lin WH, Chen WC, Yeh KH, Chen PJ, Chen DS. Depletion of beta-catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. Proc Natl Acad Sci USA 108(45): 18384-18389 (2011).
  • Weng SY, Yang CY, Li CC, Sun TP, Tung SY, Yen JJY, Tsai TF, Chen CM, Chen SH, Hsiao M, Huang PH, Yang-Yen HF. Synergism between p53 and Mcl-I in protecting from hepatic injury, fibrosis and cancer. Journal of Hepatology 54(4): 685-694 (2011).
  • Chen YF, Wu CY, Kao CH, Tsai TF*. Longevity and life span control in mammals: Lessons from the mouse. Ageing Res Rev. 9S: S28-S35 (2010).
  • Chen YF, Wu CY, Kirby R, Kao CH*, Tsai TF*. A role for the CISD2 gene in life span control and human disease. Ann. N.Y. Acad. Sci. 1201: 58-64 (2010).
  • Breuer M, Kolano A, Kwon M, Li CC, Tsai TF, Pellman D, Brunet S, Verlhac MH. HURP permits MTOC sorting for robust meiotic spindle bipolarity, similar to extra centrosome clustering in cancer cells. J Cell Biol. 191(7):1251-1260 (2010).
  • Liao YJ, Chen KH, Huang SF, Chen TL, Wang CK, Chien CH, Tsai TF, Liu SP, Chen YM. Deficiency of glycine N-methyltransferase results in deterioration of cellular defense to stress in mouse liver. Proteomics Clin. Appl. 4: 1-13 (2010).
  • Chen YF, Kao CH, Kirby R, Tsai TF*. Cisd2 mediates mitochondrial integrity and life span in mammals. Autophagy 5(7): 1043-1045 (2009).
  • Chen YF, Kao CH, Chen YT, Wang CH, Wu CY, Tsai CY, Liu FC, Yang CW, Wei YH, Hsu MT, Tsai SF, Tsai TF*. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Genes & Development 23: 1183-1194 (Cover Story; May 15, 2009).
  • Li CC, Chu HY, Yang CW, Chou CK, Tsai TF*. Aurora-A overexpression in mouse liver causes p53-dependent premitotic arrest during liver regeneration. Molecular Cancer Research 7 (5): 678-688 (Highlight Article; May 2009).
  • Chen YM, Liao YJ, Liu SP, Tsai TF. Phenotypic differences between two Gnmt-/- mouse models for hepatocellular carcinoma. Hepatology 49(6): 2130-2131 (2009).
  • Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in HBV hepatocarcinogenesis. Hepatology 49 (6): 1962-1971 (2009).
  • Yang WJ, Chang CJ, Yeh SH, Lin WH, Wang SH, Tsai TF, Chen DS, Chen PJ. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology 49(5): 1515-1524 (2009).
  • Liang CC, You LR, Chang JL, Tsai TF, Chen CM. Transgenic mice exhibiting inducible and spontaneous Cre activities driven by a bovine keratin 5 promoter that can be used for the conditional analysis of basal epithelial cells in multiple organs. J Biomed Sci. Jan 8 16: 2 (2009).
  • Yen CH, Hung JH, Ueng YF, Liu SP, Chen SY, Liu HH, Chou TY, Tsai TF, Darbha R, Hsieh LL, Chen YM. Glycine N-methyltransferase affects the metabolism of aflatoxin B(1) and blocks its carcinogenic effect. Toxicol Appl Pharmacol. 235: 296-304 (2009).
  • Liao YJ, Liu SP, Lee CM, Yen CH, Chuang PC, Chen CY, Tsai TF, Huang SF, Lee YH, Chen YM. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility. International Journal of Cancer 124 (4): 816-826 (2009).
  • Tsai CY, Chou CK, Yang CW, Lai YC, Liang CC, Chen CM, Tsai TF*. Hurp deficiency in mice leads to female infertility caused by an implantation defect. Journal of Biological Chemistry 283 (39): 26302-26306 (2008). (Accelerated Publication)
  • Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, Hsu MT, Tsai TF*. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Research 68 (6): 2033-2042 (Highlight Article; March 2008).
  • Liao AH, Cheng YC, Weng CH, Tsai TF, Lin WH, Yeh SH, Yeh WC, Li PC. Characterization of malignant focal liver lesions with contrast-enhanced 40 MHz ultrasound imaging in hepatitis B virus X transgenic mice: a feasibility study. Ultrason Imaging 30(4): 203-216 (2008).
  • Liao WL, Tsai HC, Wang HF, Chang J, Lu KM, Wu HL, Lee YC, Tsai TF, Takahashi H, Wagner M, Ghyselinck NB, Chambon P, Liu FC. Modular patterning of structure and function of the striatum by retinoid receptor signaling. Proc Natl Acad Sci U S A. 105: 6765-6770 (2008).
  • Liu SP, Li YS, Chen YJ, Chiang EP, Li AF, Lee YH, Tsai TF, Hsiao M, Hwang SF, Chen YM. Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver. Hepatology 46: 1413-1425 (2007).
  • Li CC, Chou CK, Wang MH, Tsai TF*. Overexpression of ABIN-2, a negative regulator of NF-kB, delays liver regeneration in the ABIN-2 transgenic mice. Biochemical and Biophysical Research Communications 342: 300-309 (2006).
  • Wu BK, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, Hsu MT, Tsai TF*. Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B Virus X protein transgenic mice. Biochemical and Biophysical Research Communications 340: 916-928 (2006).
  • Wu MY, Tsai TF, Beaudet AL. Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain. Genes & Development 20: 2859-2870 (2006).
  • Su JS*, Tsai TF*, Chang HM, Chao KM, Su TS, Tsai SF. Distant HNF1 site as a master control for human class I alcohol dehydrogenase gene expression. Journal of Biological Chemistry 281: 19809-19821 (2006).
  • Wu MY, Chen KS, Bressler J, Hou A, Tsai TF, Beaudet AL. Mouse imprinting defect mutations that model Angelman syndrome. Genesis 44: 12-22 (2006).
  • Hsiao YC, Chang HH, Tsai CY, Jong YJ, Horng LS, Lin SF, Tsai TF*. Coat color-tagged green mouse with EGFP expressed from the RNA polymerase II promoter. Genesis 39: 122-129 (2004).
  • Chang CW, Tsai CW, Wang HF, Tsai HC, Chen HY, Tsai TF, Takahashi H, Li HY, Fann MJ, Yang CW, Hayashizaki Y, Saito T, Liu FC. Identification of a developmentally regulated striatum-enriched zinc-finger gene, Nolz-1, in the mammalian brain. Proc. Natl. Acad. Sci. USA 101: 2613-2618 (2004).
  • Tsai TF, Bressler J, Jiang YH, Beaudet AL. Disruption of the genomic imprint in trans with homologous recombination at Snrpn in ES cells. Genesis 37: 151-161 (2003).
  • Tsai TF, Chen KS, Weber JS, Justice MJ, Beaudet AL. Evidence for translational regulation of the imprinted Snurf-Snrpn locus in mice. Hum. Mol. Genet. 11: 1659-1668 (2002).
  • Bressler J, Tsai TF, Wu MY, Tsai SF, Ramirez MA, Armstrong D, Beaudet AL. The SNRPN promoter is not required for genomic imprinting of the Prader-Willi/Angelman domain in mouse. Nature Genetics 28: 232-239 (2001).
  • Chao HK, Tsai TF, Lin CS, Su TS. Evidence that mutational activation of the ras genes may not be involved in aflatoxin B I-induced human hepatocarcinogenesis, based on sequence analysis of the ras and p53 genes. Molecular Carcinogenesis 26: 69-73 (1999).
  • Tsai TF, Jiang YH, Bressler J, Armstrong D, Beaudet AL. Paternal deletion from Snrpn to Ube3a in the mouse causes hypotonia, growth-retardation and partial lethality and provides evidence for a gene contributing to Prader-Willi syndrome. Hum. Mol. Genet. 8: 1357-1364 (1999).
  • Jiang YH, Lev-Lehman E, Bressler J, Tsai TF, Beaudet AL. Genetics of Angelman syndrome. Am. J. Hum. Genet. 65: 1-6 (1999).
  • Tsai TF, Armstrong D, Beaudet AL. Necdin deficient mice do not show lethality or the obesity and infertility of Prader-Willi syndrome. Nature Genetics 22: 15- 16 (1999).
  • Fang P, Lev-Lehman E, Tsai TF, Matsuura T, Benton CS, Sutcliff JS, Christian SL, Kubota T, Halley DJ, Meijers-Heijboer H, Langlois S, Graham JM, Jr., Beuten J, Willems PJ, Ledbetter DH, Beaudet AL. The spectrum of mutations in UBE3A causing Angelman syndrome. Hum. Mol. Genet. 8: 129-135 (1999).
  • Tsai TF, Raas-Rothschild A, Ben-Neriah Z, Beaudet AL. Prenatal diagnosis and carrier detection for a point mutation in UBE3A causing Angelman syndrome. Am. J. Hum. Genet. 63:1561-1563 (1998).
  • Jiang YH, Tsai TF, Bressler J, Beaudet AL. Imprinting in Angelman and Prader-Willi syndromes. Curr. Opin. Genet. Dev. 8: 334-342 (1998).
  • Tsai TF, Wu MJ, Su TS. The usage of cryptic splice sites in citrullinemia fibroblast suggests a role of polyadenylation in splice site selection during terminal exon definition. DNA Cell Biol. 17: 717-725 (1998).
  • Wang SY, Chen LY. Tsai TF, Su TS, Choo KB, Ho CK. Constitutive production of colony-stimulating factors by human hepatoma cell lines possible correlation with cell differentiation. Exp. Hematol. 24:437-444(1996).
  • Tsai TF, Su TS. A nuclear post-transcriptional event responsible for overproduction of argininosuccinate synthetase in a canavanine-resistant variant of a human epithelial cell line. Eur. J. Biochem. 229:233-238 (1995).
  • Lui WY, P'eng FK, Chang YF, Chang TJ, Tsai TF, Hsu ML, Su TS, Tsay SH, Wu CW, Liu TY, et al. Analysis of glucocorticoid receptors in human hepatocellular carcinoma and HepG2 cells. Hepatology 18(5):1167-1174 (1993).
  • Lin CH, Hsiao KJ, Tsai TF, Chao HK, Su TS. Identification of a missense phenylketonuria mutation at codon 408 in Chinese. Hum Genet. 89(6):593-596 (1992).
  • Soong BW, Tsai TF, Su CH, Kao KP, Hsiao KJ, Su TS. DNA polymorphisms and deletion analysis of the Duchenne-Becker muscular dystrophy gene in the Chinese. Am J Med Genet. 38(4):593-600 (1991).
  • Tsai TF, Hsiao KJ, Su TS. Phenylketonuria mutation in Chinese haplotype 44 identical with haplotype 2 mutation in northern-European Caucasians. Hum Genet. 84(5):409-411 (1990).
  • Su TS, Tsai TF, Chi CW, Han SH, Chou CK. Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma. Hepatology 11(1):118-122 (1990).
  • Tsai TF, Yauk YK, Chou CK, Ting LP, Chang C, Hu CP, Han SH, Su TS. Evidence of autocrine regulation in human hepatoma cell lines. Biochem Biophys Res Commun. 153(1):39-45 (1988).

    產學合作

  • Title: Toward the translational application of Cisd2 activator PZ-19a and PZ-19b in cosmetics;
    Project Period: Nov.16, 2016 - Dec. 31, 2017;
    Budget: NT 5,000,000;
    PI: Ting-Fen Tsai
  • Title: Study the beneficial effects of PZ-19 on UVB-induced skin damages and its application in food supplements;
    Project Period: Jan. 1, 2018 - Dec. 31, 2019;
    Budget: NT 3,000,000;
    PI: Ting-Fen Tsai

    專利申請

  • 類別:U.S. Patent Application Serial No. 10/700,158
    專利名稱:Combinational Usage of Insulators and Coat Color Marker for High Efficiency Transgene Expression and Visual Genotyping in Mice.
    國別:The United States Patent and Trademark Office
    專利號碼:United States Patent 7,067,715
    發明人:Tsai TF, Hsiao YC, Hu MC, Chang HH, Wu YF.
    專利權人:National Yang-Ming University & Level Biotechnology Inc.
    專利期間:Filing date on Nov. 3, 2003; Accepted and approved on June 27, 2006
    計畫編號:教育部卓越計畫89-B-FA22-2-4
  • 類別:U.S. Provisional Patent Application
    專利名稱:CISD2-Konckout Mice and Uses Thereof
    國別:The United States Patent and Trademark Office
    專利號碼:US Patent Application 20080104719; Application number 11/866374
    發明人:Tsai TF, Chen YF, Tsai SF, and Chen YT
    專利權人:National Yang-Ming University & National Health Research Institutes
    專利期間:Filing date Oct. 2, 2007; Publication date May 1, 2008
    計畫編號:NSC 95HC007 and NSC95-2752-B-010-004-PAE
  • 類別:U.S. Provisional Patent Application
    專利名稱:Methods and Compositions for the Treatment and Prevention of Aging-associated Conditions
    國別:The United States Patent and Trademark Office
    專利號碼:Docket number N023-0003USP1
    發明人:Tsai TF, Chen YF, Wu CY, Wang CH, and Tsai SF
    專利權人:National Yang-Ming University
    專利期間:Filing date Nov. 3, 2011
    計畫編號:NSC97-2320-B-010-015-MY3
  • 類別:中華民國專利
    專利名稱:防止皮膚老化相關症狀的醫藥組合物及其使用方法
    國別:中華民國
    專利號碼:中華民國專利 發明第I614031號 (Docket number 2011RDPA013)
    發明人:Tsai TF, Chen YF, Wu CY, Wang CH, and Tsai SF
    專利權人:National Yang-Ming University
    專利期間:2018年2月11日至2032年11月1日止
    計畫編號:NSC97-2320-B-010-015-MY3
  • 類別:中國大陸專利
    專利名稱:用於治療和預防老化相關症狀的方法和組合
    國別:中國
    專利號碼:Docket number 27713
    發明人:Tsai TF, Chen YF, Wu CY, Wang CH, and Tsai SF
    專利權人:National Yang-Ming University
    專利期間:Filing date Oct. 2012
    計畫編號:NSC97-2320-B-010-015-MY3

    技術移轉

  • 技術名稱:金黃毛色暨高效基因表現轉殖鼠
    專利名稱:Combinational Usage of Insulators and Coat Color Marker for High Efficiency Transgene Expression and Visual Genotyping in Mice.
    專利號碼:美國專利7,067,715
    授權單位:國立陽明大學基因體研究中心
    被授權單位:進階生物科技股份有限公司
    合約期間:92年1月1日起
  • 技術名稱:開發PZ-19a和PZ-19b在美妝保養品及食品之應用(Toward the translational application of PZ-19a and PZ-19b in cosmetics and food supplements for anti-aging of skin)
    授權單位:國立陽明大學生命科學系暨基因體科學研究所
    被授權單位:友華生技醫藥股份有限公司
    合約期間:106年11月20日至126年11月19日(20年)